UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 31, 2013

 

 

Horizon Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35238   27-2179987
(State of incorporation)  

(Commission

File No.)

 

(IRS Employer

Identification No.)

520 Lake Cook Road, Suite 520, Deerfield, Illinois 60015

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (224) 383-3000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

Set forth below are the results of the matters submitted for a vote of stockholders at our 2013 Annual Meeting of Stockholders held on May 31, 2013.

Proposal 1 — Election of Directors

The following directors were elected to serve for three-year terms until the 2016 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.

 

Director Elected

   Number of Shares
Voted  For
     Number of Shares  Voted
Against or Withheld
     Broker Non-Votes  

Jean-Francois Formela, M.D.

     33,452,878         181,031         13,659,921   

Jeff Himawan, Ph.D.

     31,525,137         2,108,772         13,659,921   

Proposal 2 — Ratification of the Appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2013.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

46,718,447   555,264   20,119   0

Proposal 3 — Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

29,528,356   2,037,360   2,068,193   13,659,921


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 3, 2013     Horizon Pharma, Inc.
    By:  

/s/ Robert J. De Vaere

      Robert J. De Vaere
      Executive Vice President and Chief Financial Officer